Printed From:

Significant A1C reductions and demonstrated safety in a broad range of adult patients1-3

 

Hypothetical patient profiles. Individual results may vary.

 

Select a patient with Type 1 or Type 2 Diabetes to see efficacy and safety results from the 4 EDITION clinical studies

 

test

 

EDITION 3: T2DM, Insulin-naive patients with noninsulin antidiabetic drugs1-3

Meet Ray, a 48-year-old insulin-naive patient with T2DM, who plays guitar for a jazz band and is constantly on the go. He was concerned about how adding another medication would affect his busy lifestyle.

Hypothetical patient profile. Individual results may vary.

x

There were no clinically important differences in body weight between treatment groups.1

FPG, fasting plasma glucose; OADs, oral antidiabetic drugs; T2DM, type 2 diabetes mellitus.
aModified intent to treat population.
bSevere hypoglycemia: an event requiring assistance of another person to actively administer a resuscitative action.
cDocumented symptomatic hypoglycemia: an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value ≤54 mg/dL.

References:

  1. Toujeo Prescribing Information.
  2. Data on file. EDITION 3 CSR. Sanofi.
  3. Bolli GB, Riddle MC, Bergenstal RM, et al; the EDITION 3 Study Investigators. Diabetes Obes Metab. 2015;17(4):386-394.
  4. American Diabetes Association. Diabetes Care. 2017;40(suppl 1):S1-S135.
 

test

 

EDITION 2: T2DM, Basal insulin switch patients1-3

Previously on basal insulin and oral antidiabetic drugs with noninsulin antidiabetic drugs

Meet Sofia. She works all week and teaches salsa dancing on the weekends. She is a 46-year-old T2DM patient with commercial insurance who was having trouble getting to goal on a basal insulin and OADs.

Hypothetical patient profile. Individual results may vary.

x

There were no clinically important differences in body weight between treatment groups.1

FPG, fasting plasma glucose; OADs, oral antidiabetic drugs; T2DM, type 2 diabetes mellitus.
aModified intent to treat population.
bSevere hypoglycemia: an event requiring assistance of another person to actively administer a resuscitative action.
cDocumented symptomatic hypoglycemia: an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value ≤54 mg/dL.

References:

  1. Tuojeo Prescribing Information.
  2. Data on file. EDITION 2 CSR. Sanofi.
  3. Yki-Järvinen H, Bergenstal R, Ziemen M, et al; the EDITION 2 Study Investigators. Diabetes Care. 2014;37(12):3235-3243.
  4. American Diabetes Association. Diabetes Care. 2017;40(suppl 1):S1-S135.
 

test

 

EDITION 1: T2DM, Basal insulin switch patients + mealtime1,3

Previously on basal and mealtime insulin ± metformin

Meet Frank, a T2DM patient with commercial insurance. He is a 64-year-old security guard by day and trumpet player by night. He wasn't reaching his glycemic goal on Lantus® 60 Units and mealtime insulin.

Hypothetical patient profile. Individual results may vary.

x

There were no clinically important differences in body weight between treatment groups.1

FPG, fasting plasma glucose; OADs, oral antidiabetic drugs; T2DM, type 2 diabetes mellitus.
aModified intent to treat population.
bSevere hypoglycemia: an event requiring assistance of another person to actively administer a resuscitative action.
cDocumented symptomatic hypoglycemia: an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value ≤54 mg/dL.

References:

  1. Toujeo Prescribing Information.
  2. Data on file. EDITION 1 CSR. Sanofi.
  3. Riddle MC, Bolli GB, Ziemen M, et al; the EDITION 1 Study Investigators. Diabetes Care. 2014;37(10):2755-2762.
  4. American Diabetes Association. Diabetes Care. 2017;40(suppl 1):S1-S135.
 

test

 

EDITION 4: T1DM1-3

Previously on basal and mealtime insulin with mealtime insulin analog

Meet Meg, a 22-year-old with T1DM. She is concerned about how administering basal insulin will fit into her highly active life as a classical music professional

Hypothetical patient profile. Individual results may vary.

x

There were no clinically important differences in body weight between treatment groups.1

FPG, fasting plasma glucose; OADs, oral antidiabetic drugs; T2DM, type 2 diabetes mellitus.
aModified intent to treat population.
bSevere hypoglycemia: an event requiring assistance of another person to actively administer a resuscitative action.
cDocumented symptomatic hypoglycemia: an event with typical symptoms of hypoglycemia accompanied by a self-monitored plasma glucose value ≤54 mg/dL.

References:

  1. Toujeo Prescribing Information.
  2. Data on file. EDITION 4 CSR. Sanofi.
  3. Home PD, Bergenstal RM, Bolli GB, et al; the EDITION 4 Study Investigators. Diabetes Care. 2014;38(12):2217-2225.
  4. American Diabetes Association. Diabetes Care. 2017;40(suppl 1):S1-S135.